FBRX
Forte BiosciencesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull view is that May 11, 2026 earnings mainly reinforced the existing thesis: runway looks materially better after the April financing, FB102 now carries FDA Fast Track designation in celiac disease, and multiple 2026 readouts remain live. The immediate earnings release was operationally supportive rather than thesis-breaking.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +15.9.
What can break
Even after the April 2026 financing, management still frames runway as at least twelve months from the May 11, 2026 10-Q filing date, so future capital needs cannot be ruled out if timelines slip or development expands.
Momentum
5
Value
41
Sentiment
69
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $21.00 · Bull $36.00 · Bear $11.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-16 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $64.75
Why
Momentum5 · Δ7d -2.8
Value41 · Δ7d +0.1
Sentiment69 · Δ7d +15.9
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
5
34% active weight
Current posture
7d trendFlat
Δ7d
-2.8
Δ21d
-70.8
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
69
33% active weight
Current posture
7d trendImproving
Δ7d
+15.9
Δ21d
+2.4
Why this grade
Composite grade F. Momentum 5.4 / Value 41.1 / Sentiment 68.8
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$394.01M
Beta
3.22
Shares Out
12.53M
P/E (TTM) · Derived
-2.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-8.30
Rev YoY
-
EPS YoY
+78.1%
Gross Margin
-
Op Margin
-
Net Debt
-$58.37M
Current Ratio
7.34
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology